Finanical Reports

Explore the landscape of Finanical Reports in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Finanical Reports to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

anatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer
CompanyDrug

Danatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer

Danatlas Pharmaceuticals announced that the first subject has been enrolled and dosed in the Phase II clinical study of DAT‑2645, the company's independently developed Class 1 innovative drug, at the…

Danatlas Pharmaceuticals Wins NMPA IND Approval for DAT‑6618 – China's First PPARγ Inhibitor to Enter Clinical Development

Danatlas Pharmaceuticals Wins NMPA IND Approval for DAT‑6618 – China’s First PPARγ Inhibitor to Enter Clinical Development

Ribo Life Science Opens Automated Intelligent Drug Screening Center – A Key Leap in AI‑Powered siRNA Drug Discovery

Ribo Life Science Opens Automated Intelligent Drug Screening Center – A Key Leap in AI‑Powered siRNA Drug Discovery

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Company

Lee’s Pharmaceutical Reports Q3 2022 Financials with 8.8% Revenue Growth

Company

BeiGene Reports 88% YOY Revenue Growth in Q3 2022

Company

Novo Nordisk Reports 16% YOY Growth in Q3, Raises Full-Year Guidance

Company

Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline

Company

Sanofi’s Q3 Sales Rise 9% on Dupixent and Flu Vaccine

Company

Junshi Biosciences Reports 55% Drop in Q3 Revenues

Company

RemeGen Reports 397.47% YOY Revenue Growth in Q3 2022

Company

Shanghai Pharmaceuticals Reports 12.86% YOY Revenue Growth in Q3 2022

Show More